Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from Meihao Medical Group Co., Ltd. ( (HK:1947) ) is now available.
Meihao Medical Group Co., Ltd. has issued a supplemental announcement providing detailed disclosure of the valuation methodology used for its previously announced subscription of 2,863,492 Class B ordinary shares in Deepcare Medical Holdings Limited, a fertility services company in Thailand. The company elaborated on its use of the income approach and discounted cash flow method, specifying the parameters applied to derive the weighted average cost of capital, including cost of equity, cost of debt, tax rate, risk-free rate, beta, market risk premium, and an enterprise-specific risk adjustment that factors in industry and Thailand country risks. By clarifying these valuation inputs and assumptions, Meihao aims to enhance transparency around the economic basis for the investment, which may help investors better assess the risk-return profile of its expansion into assisted reproductive services and its broader international growth strategy.
More about Meihao Medical Group Co., Ltd.
Meihao Medical Group Co., Ltd., listed in Hong Kong, operates in the medical and healthcare services sector with a focus on assisted reproductive and fertility-related services, including investments in overseas fertility service providers such as those in Thailand.
Average Trading Volume: 85,401
Technical Sentiment Signal: Buy
Current Market Cap: HK$213.1M
For a thorough assessment of 1947 stock, go to TipRanks’ Stock Analysis page.